Editas Medicine Inc
EDIT
Get informed when a big investor buys or sells
+ FollowMarket Cap$445.04M
Close$
$-1.25
151.1% downside
Current Fair Value
151.1% downsideOvervalued by 151.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $445.04 Million |
|---|---|
| Enterprise Value | $311.05 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.8 |
| Beta | 2 |
| Outstanding Shares | 119,294,615 |
Return
| Return on Equity | -70.24% |
|---|---|
| Return on Assets | -31.15% |
| Return on Invested Capital | 62.24% |
Valuation & Multiples
| P/E Ratio | -3.88 |
|---|---|
| PEG | 5.9 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 7.04 |
| Enterprise Value to EBIT | 2.96 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | 0.45 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
$2.85 M
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.21
Average shareholder expectationRevenue Estimate
$4.53 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 36.42% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.05%▼ 100.69% |
|---|---|
| Total Invested | $138,197▼ 99.96% |
| Investors Holding | 7▼ 218.00% |
ESG Score
No data
About Editas Medicine Inc
87 employees
CEO: Cynthia Collins Editas Medicine, Inc. is a clinical-stage company dedicated to developing innovative genomic medicines that address a range of serious diseases. The company utilizes its proprietary gene editing platform, which is founded on CRISPR techn...